7 min listen
ACR2022 - Day 3.2
FromRheumnow Podcast
ratings:
Length:
34 minutes
Released:
Nov 14, 2022
Format:
Podcast episode
Description
Bouncebackability portends increased risk of adverse outcomes in RA
Dr. Richard Conway discusses Abstract 2218 at ACR22 Convergence.
Abstract 2218: Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia.
Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Efficacy and Safety Results from BE OPTIMAL in PsA
Dr. Arthur Kavanaugh discusses abstract L02 ACR22 Convergence in Philadelphia, PA.
L02: Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Hydroxychloroquine Update from ACR22
Dr. Michelle Petri reviews several abstracts presented at ACR22 Convergence.
Abstracts 0343, 0538, 0976, 0983, 0981, 0980
RA: Steroids are bad, again
Dr. Richard Conway discusses Abstract 2219 at ACR22 Convergence
Abstract 2219: Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Tofacitinib and RA-ILD
Dr. Richard Conway discusses Abstract 2251 at ACR22 Convergence.
Abstract 2251: Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
Life or Organ Threatening SLE: What To Do? Is There Anything New?
Dr. Michelle Petri discusses Abstracts 1651, 1677 at ACR22 Convergence in Philiadelphia, PA.
Dr. Richard Conway discusses Abstract 2218 at ACR22 Convergence.
Abstract 2218: Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia.
Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Efficacy and Safety Results from BE OPTIMAL in PsA
Dr. Arthur Kavanaugh discusses abstract L02 ACR22 Convergence in Philadelphia, PA.
L02: Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Hydroxychloroquine Update from ACR22
Dr. Michelle Petri reviews several abstracts presented at ACR22 Convergence.
Abstracts 0343, 0538, 0976, 0983, 0981, 0980
RA: Steroids are bad, again
Dr. Richard Conway discusses Abstract 2219 at ACR22 Convergence
Abstract 2219: Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Tofacitinib and RA-ILD
Dr. Richard Conway discusses Abstract 2251 at ACR22 Convergence.
Abstract 2251: Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
Life or Organ Threatening SLE: What To Do? Is There Anything New?
Dr. Michelle Petri discusses Abstracts 1651, 1677 at ACR22 Convergence in Philiadelphia, PA.
Released:
Nov 14, 2022
Format:
Podcast episode
Titles in the series (100)
The RheumNow Week n Review - 29 April 2017: The RheumNow Week n Review - 29 April 2017 by Dr. Cush by Rheumnow Podcast